Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun;193(6):1909-1923.
doi: 10.1007/s12010-020-03475-8. Epub 2021 Jan 29.

Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations

Jaganathan Ramakrishnan  1 , Saravanan Kandasamy  2 , Ancy Iruthayaraj  1 , Sivanandam Magudeeswaran  1 , Kalaiarasi Chinnasamy  1 , Kumaradhas Poomani  3
Affiliations

Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations

Jaganathan Ramakrishnan et al. Appl Biochem Biotechnol. 2021 Jun.

Abstract

The unprecedented coronavirus SARS-CoV-2 outbreak at Wuhan, China, caused acute respiratory infection to humans. There is no precise vaccine/therapeutic agents available to combat the COVID-19 disease. Some repurposed drugs are saving the life of diseased, but the complete cure is relatively less. Several drug targets have been reported to inhibit the SARS-CoV-2 virus infection, in that TMPRSS2 (transmembrane protease serine 2) is one of the potential targets; inhibiting this protease stops the virus entry into the host human cell. Camostat mesylate, nafamostat, and leupeptin are the drugs, in which the first two drugs are being used for COVID-19 and leupeptin also tested. To consider these drugs as the repurposed drug for COVID-19, it is essential to understand their binding affinity and stability with TMPRSS2. In the present study, we performed the molecular docking and molecular dynamics (MD) simulation of these molecules with the TMPRSS2. The docking study reveals that leupeptin molecule strongly binds with TMPRSS2 protein than the other two drug molecules. The RMSD and RMSF values of MD simulation confirm that leupeptin and the amino acids of TMPRSS2 are very stable than the other two molecules. Furthermore, leupeptin forms interactions with the key amino acids of TMPRSS2 and the same have been maintained during the MD simulations. This structural and dynamical information is useful to evaluate these drugs to be used as repurposed drugs, however, the strong binding profile of leupeptin with TMPRSS2, suggests, it may be considered as a repurposed drug for COVID-19 disease after clinical trial.

Keywords: Binding affinity; Molecular docking; Molecular dynamics; Repurposed drug; SARS-CoV-2; TMPRSS2.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Chemical structure of the drug molecules
Fig. 2
Fig. 2
Intermolecular interactions and planner (2D) view of ligands with active site residues of TMPRSS2 complexes. a Camostat mesylate. b Nafamostat. c Leupeptin
Fig. 3
Fig. 3
Connolly surface map showing the superimpose of ligands in the active site environment of TMPRSS2. Camostat mesylate (green), nafamostat (pink), and leupeptin (cyan)
Fig. 4
Fig. 4
RMSD of three ligand-TMPRSS2 complexes during the MD simulation
Fig. 5
Fig. 5
RMSF of three ligand-TMPRSS2 complexes during the MD simulation
Fig. 6
Fig. 6
Superimposed view of ligand-TMPRSS2 complexes from molecular docking and MD simulations
Fig. 7
Fig. 7
Intermolecular interactions of (a) camostat mesylate, (b) nafamostat, and (c) leupeptin in the active site of TMPRSS2 at 100 ns of MD simulations
Fig. 8
Fig. 8
Different types of intermolecular interactions and their stability during the MD simulation
Fig. 9
Fig. 9
2D view of intermolecular interactions of three ligands—TMPRSS2 and their stability (%) during the MD simulations
See this image and copyright information in PMC

References

    1. Woo PC, Huang Y, Lau SK, Yuen KY. Coronavirus genomics and bioinformatics analysis. Viruses. 2010;2(8):1804–1820. doi: 10.3390/v2081803. - DOI - PMC - PubMed
    1. Woo PC, Lau SK, Lam CS, Lau CC, Tsang AK, Lau JH, Bai R, Teng JL, Tsang CC, Wang M, Zheng BJ, Chan KH, Yuen KY. Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus. Journal of Virology. 2012;86(7):3995–4008. doi: 10.1128/JVI.06540-11. - DOI - PMC - PubMed
    1. Kuiken T, Fouchier RA, Schutten M, Rimmelzwaan GF, van Amerongen G, van Riel D, Laman JD, de Jong T, van Doornum G, Lim W, Ling AE, Chan PK, Tam JS, Zambon MC, Gopal R, Drosten C, van der Werf S, Escriou N, Manuguerra JC, Stöhr K, Peiris JS, Osterhaus AD. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. The Lancet. 2003;362(9380):263–270. doi: 10.1016/S0140-6736(03)13967-0. - DOI - PMC - PubMed
    1. Zhong NS, Zheng BJ, Li YM, Poon, Xie ZH, Chan KH, Li PH, Tan SY, Chang Q, Xie JP, Liu XQ, Xu J, Li DX, Yuen KY, Peiris, Guan Y. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003. The Lancet. 2003;362(9393):1353–1358. doi: 10.1016/S0140-6736(03)14630-2. - DOI - PMC - PubMed
    1. Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. The Lancet. 2015;386(9997):995–1007. doi: 10.1016/S0140-6736(15)60454-8. - DOI - PMC - PubMed

LinkOut - more resources